1030P - Survival rates in high-risk neuroblastoma patients undergoing anti-GD2 immunotherapy: A single arm meta-analysis and systemic review

Background

High-risk Neuroblastoma presents a clinical challenge due to its poor prognosis, with some studies showing a 43% 5-year survival rate in newly diagnosed cases and a 21% 1-year event-free survival rate in relapsed patients. Immunotherapy targeting anti-disialoganglioside (anti-GD2) has emerged as a promising strategy, with agents like Dinutuximab and Naxitamab showing the potential to improve survival outcomes. This meta-analysis aims to assess the impact of anti-GD2 drugs on survival rates in patients with High-risk Neuroblastoma, offering valuable insights into their therapeutic effectiveness.

Methods

We systematically searched Pubmed, Cochrane, and EMBASE for clinical trials and prospective cohorts between 2004 and 2023 utilizing anti-GD2 drugs in patients with high-risk neuroblastoma. We pooled the prevalence and the 95% confidence intervals (CI) for the outcomes of interest: overall survival (OS), event-free survival (EFS) progression-free survival (PFS). Heterogeneity was assessed using I² statistics. A random-effects model was used for all outcomes. Statistical analyses were performed using R software version 4.3.2.

Results

A total of 19 studies involving 2999 patients were included in the analysis. Among these, five studies assessed Dinutuximab; six assessed Dinutuximab beta; four investigated Naxitamab; two examined hu14.18K322A, and two evaluated 3F8. Among the patients included, 634 (21%) had relapsed or refractory disease, with ages ranging from 1 to 21 years. In the pooled analysis, among relapsed or refractory patients, the 3-year EFS or PFS was 45.99% (95% CI 36.86-55.39), while the OS rate reached 65.33% (95% CI 59.24-70.96). Among newly diagnosed patients, the 5-year EFS rate was 56.44% (95% CI 52.75-60.05) and the 5-year OS rate was 68.25% (95% CI 62.66-73.36). Subgroup analyses revealed comparable OS rates among patients treated with Dinutuximab, with or without interleukin 2, and across different infusion durations, with no significant difference observed between the groups.

Conclusions

This single-arm meta-analysis suggests that high-risk Neuroblastoma patients may benefit from anti-GD2 immunotherapy, with promising impacts on OS, PFS, and EFS.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.